Date: 2014-04-09
Type of information: Private placement
Company: Quantum Genomics (France)
Investors: Thétys (France) and other institutional investors
Amount: €3.4 million
Funding type: private placement
Planned used: This capital increase will be used to support both Quantum Genomics \'development and research programmes. The company intends to initiate the second clinical phase of its most advanced product in treating hypertension, QGC001. QGC001 is the first molecule of a new class of antihypertensive agents known as BAPAI (Brain Aminopeptidase A Inhibitors). The inhibition of Brain Aminopeptidase A induces three pharmacological effects required to treat hypertension and related cardiovascular diseases: a decrease in vascular resistance, a decrease production of antidiuretic hormon and a regulation in the heart rate. QGC001 aims to provide a therapeutic alternative to the treatment of hypertension, particularly for patients with a specific hormonal profile, characterised by a lowered concentration of renin and a higher level of vasopressin (LRVH profile), whose blood pressure is more difficult to control with conventional systemic renin-angiotensin system blockers. In early 2014, the Agence Nationale de la Recherche (ANR - French National Research Agency) already granted a subsidy of €1 million to Quantum Genomics and its partners, Inserm and the Hôpital Européen Georges-Pompidou (Georges Pompidou European Hospital), with a view to conducting phase IIa of QGC001. These funds will also contribute to pursuing three further axes of development within thecompany: a) to complement the findings of the preclinical programme for the prevention and treatment ofcardiac insufficiency, b) to advance the preclinical phases of the ‘best-in-class’ product derived from QGC001 and c) to continue studies of combinations with other antihypertensive agents.
Others: * On April 9, 2014, Quantum Genomics, a biopharmaceutical research company developing new treatments in the field ofcardiovascular diseases, has announced a capital increase gained through private placements totalling €3.4 million through the issuance of 637,334 new shares at a unit price of €5.35. Following this transaction, Quantum Genomics has announced both the transfer and the resumption of trading of its securities on the Alternext market of Euronext Paris from 10 April, 2014. These securities will be listed continuously and a liquidity agreement is being drawn up with Aurel BGC. The ISIN code remains unchanged (FR0011648971) whereas the ticker symbol will become ALQGC from said date. At the end of the transaction, the distribution of Quantum Genomics social capital is as follows: -Long-standing family offices 47,39% - Managers 17,27% - New private placement investors (including Téthys) 9,98% - Floating 25,36%.
Therapeutic area: Cardiovascular diseases
